Shihong Sheng

Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) with Psoriatic Disease: Exploratory Assessments from a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)

Objectives PsA affects ~20-30% of patients with PsO, causing articular inflammation and impaired quality of life. ICO, a novel targeted oral peptide that binds IL-23 receptor, showed greater clinical response rates vs placebo and a favorable safety profile in moderate-to-severe p...